February 11, 2020 / 12:37 PM / 8 days ago

BRIEF-Karyopharm And Promedico Enter Agreement To Commercialize Xpovio (Selinexor) In Israel

Feb 11 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM AND PROMEDICO, A MEMBER OF THE NEOPHARM GROUP, ENTER INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE XPOVIO® (SELINEXOR) IN ISRAEL

* KARYOPHARM THERAPEUTICS - RETAINED EXCLUSIVE PRODUCTION RIGHTS AND WILL SUPPLY FINISHED PRODUCT FOR COMMERCIAL USE IN COVERED TERRITORY

* KARYOPHARM THERAPEUTICS INC - KARYOPHARM IS ALSO ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON FUTURE NET SALES OF XPOVIO IN COVERED TERRITORY

* KARYOPHARM THERAPEUTICS INC - PROMEDICO WILL RECEIVE EXCLUSIVE RIGHTS TO COMMERCIALIZE XPOVIO IN COVERED TERRITORY

* KARYOPHARM THERAPEUTICS INC - PROMEDICO IS RESPONSIBLE FOR ALL REGULATORY FILINGS AND OBLIGATIONS REQUIRED FOR REGISTERING XPOVIO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below